Industry News

  • FDA Approves Tarlatamab-dlle for Extensive-Stage Small Cell Lung Cancer

    On May 16, the US Food and Drug Administration granted accelerated approval to tarlatamab-dlle for extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.

    For more information read the FDA announcement and the Amgen Inc. announcement

    Posted 5/20/2024



  • FDA Approves Lisocabtagene Maraleucel for Follicular Lymphoma

    On May 15, the US Food and Drug Administration (FDA) granted accelerated approval to lisocabtagene maraleucel for adults with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.

    For more information read the FDA announcement.

    Posted 5/16/2024



  • FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer

    On April 29, the US Food and Drug Administration (FDA) granted traditional approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tisotumab vedotin-tftv previously received accelerated approval for this indication.

    For more information read the FDA announcement and the Pfizer announcement

    Posted 4/30/2024



  • FDA Approves Lutetium Lu 177 Dotatate for Pediatric Patients with Astroenteropancreatic Neuroendocrine Tumors

    On April 23, the US Food and Drug Administration (FDA) approved lutetium Lu 177 dotatate for pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors.

    For more information read the FDA announcement.

    Posted 4/24/2024



  • FDA Approves Nogapendekin Alfa Inbakicept-pmln for Invasive Bladder Cancer

    On April 22, the US Food and Drug Administration approved nogapendekin alfa inbakicept-pmln in combination with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.

    For more information read the FDA announcement.

    Posted 4/23/2024



  • FDA Approves Alectinib for ALK-positive Non-Small Cell Lung Cancer

    On April 18, the US Food and Drug Administration (FDA) approved alectinib for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer, as detected by an FDA-approved test.

    For more information read the FDA announcement and the Genentech Inc. announcement

    Posted 4/18/2024



  • FDA Approves Idecabtagene vicleucel for Relapsed or Refractory Multiple Myeloma

    On April 4, the US Food and Drug Administration (FDA) approved idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma after 2 or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. 

    For more information read the Bristol Myers Squibb announcement.

    Posted 4/9/2024



  • FDA Approves Fam-trastuzumab deruxtecan-nxki for Unresectable or Metastatic HER2-positive Solid Tumors

    On April 5, the US Food and Drug Administration (FDA) granted accelerated approval to fam-trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.

    For more information read the FDA announcement.

    Posted 4/8/2024



  • FDA Approves Mirvetuximab Soravtansine-gynx for Certain Ovarian Cancers

    On March 22, the US Food and Drug Administration (FDA) approved mirvetuximab soravtansine-gynx for adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received 1 to 3 prior systemic treatment regimens. 

    For more information read the FDA announcement and the AbbVie announcement

    Posted 3/25/2024



  • FDA Approves Oral Suspension Ibrutinib in Adults with Chronic Lymphocytic Leukemia & Small Lymphocytic Lymphoma

    On February 24, the US Food and Drug Administration (FDA) approved a label expansion for ibrutinib with an oral suspension formulation for adult patients in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. Ibrutinib is now the only Bruton’s tyrosine kinase inhibitor (BTKi) approved with an oral suspension formulation.

    For more information read the Johnson & Johnson announcement.

    Posted 3/21/2024




1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
ncoa-northcarolina.com
Email Us